PET of αvβ3-integrin and αvβ5-integrin expression with 18F-fluciclatide for assessment of response to targeted therapy: Ready for prime time?

Journal of Nuclear Medicine

Volumn 52, Issue 3, 2011, Pages 335-337

  Beer, Ambros J ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AH 111585; ALPHAVBETA5 INTEGRIN; DOTA RGD CU 64; FLUCICLATIDE F 18; FLUORODEOXYGLUCOSE C 14; FLUORODEOXYGLUCOSE F 18; GALACTO RGD F 18; GLUCOSAMINO RGD TC 99M; PACLITAXEL; RADIOPHARMACEUTICAL AGENT; SUNITINIB; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANGIOGENESIS INHIBITOR; DIAGNOSTIC AGENT; INDOLE DERIVATIVE; MACROGOL DERIVATIVE; PEPTIDE; PYRROLE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DOSIMETRY; GLIOMA; HUMAN; LOW DRUG DOSE; LUNG CANCER; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR VASCULARIZATION; ANIMAL; GLIOBLASTOMA; MALE; METABOLISM; MOUSE; NOTE; NUDE MOUSE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; INDOLES; INTEGRIN ALPHAVBETA3; MALE; MICE; MICE, NUDE; PEPTIDES; POLYETHYLENE GLYCOLS; PYRROLES; RADIOPHARMACEUTICALS; RECEPTORS, VITRONECTIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 79952810411     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.078568     Document Type: Review

References (20)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
2. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science. 2006;312:1171-1175.
3. Chow LQM, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884-896. (Pubitemid 350002890)
4. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264:569-571.
5. 5-integrin imaging agent. J Nucl Med. 2011;52:424-430.
6. 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med. 2009;50:116-122.
7. 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J Nucl Med. 2006;47:2000-2007.
8. Dumont RA, Hildebrandt I, Su H, et al. Noninvasive imaging of αVβ3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res. 2009;69:3173-3179.
9. 18F]galacto-RGD. PLoS Med. 2005;2:e70.
10. 18F]fluorinated aldehyde-containing prosthetic groups. Bioconjug Chem. 2008;19:951-957.
11. 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879-886.
12. 18F-AH111585 in healthy volunteers. J Nucl Med. 2008;49:1664-1667.
13. Gaertner FC, Schwaiger M, Beer AJ. Molecular imaging of αvβ3 expression in cancer patients. Q J Nucl Med Mol Imaging. 2010;54:309-326.
14. 18F]galacto-RGD identifies the level of integrin αvβ3 expression in man. Clin Cancer Res. 2006;12:3942-3949.
15. Weber WA. Assessing tumor response to therapy. J Nucl Med. 2009;50(suppl 1):S1-S10.
16. 18F]fluorothymidine. Methods. 2009;48:205-215.
17. Galbraith SM. Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development. Br J Radiol. 2003;76(suppl 1):S83-S86. (Pubitemid 39530319)
18. Brix G, Griebel J, Kiessling F, Wenz F. Tracer kinetic modelling of tumour angiogenesis based on dynamic contrast-enhanced CT and MRI measurements. Eur J Nucl Med Mol Imaging. 2010;37 (suppl 1):30-51.
19. Zweifel M, Padhani AR. Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools? Eur J Nucl Med Mol Imaging. 2010;37(suppl 1):164-182.
20. 18F]AH-111585 PET imaging to detect tumours and angiogenesis. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00565721. Updated March 25, 2010. Accessed January 3, 2011.